Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes (Q38129805)

29 August 2017

Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes (English)

1 reference

29 August 2017

0 references

Jeff Unger

1

1 reference

29 August 2017

1 October 2013

1 reference

29 August 2017

Current diabetes report

1 reference

29 August 2017

13

1 reference

29 August 2017

663-668

1 reference

29 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-013-0404-x

29 August 2017

0 references

cites work

Type 2 diabetes: an expanded view of pathophysiology and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Type 1 diabetes: recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Off-label prescribing among office-based physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0404-X

Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment

21 January 2018

1 reference

12 December 2020

Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM

1 reference

12 December 2020

Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes

1 reference

12 December 2020

Intestinal Factors in the Control of Insulin Secretion

1 reference

12 December 2020

Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists

1 reference

12 December 2020

10.1007/S11892-013-0404-X

Identifiers

DOI

1 reference

PubMed ID

23955813

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23955813